Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity

Biochemical Pharmacology

Volumn 56, Issue 10, 1998, Pages 1315-1322

  Pavillard, Valérie ^a   Formento, Patricia ^a   Rostagno, Philippe ^a   Formento, Jean Louis ^a   Fischel, Jean Louis ^a   Francoual, Mireille ^a   Etienne, Marie Christine ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

5fluorouracil; Colorectal cancer; Drug combination; Irinotecan; SN38; Tumoral cell lines

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; IRINOTECAN; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; TUMOR CELLS, CULTURED;

EID: 0031771777     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00205-6     Document Type: Article

References (30)

1. Trichopoulos D, Petridou E, Lipworth L and Adami HO, Epidemiology of cancer. In: Cancer, Principles and Practice of Oncology. (Eds. De Vita VT, Hellman S and Rosenberg SA), pp. 231-257. Lippincott-Raven, Philadelphia, 1997.
2. Advanced Colorectal Cancer Meta-Analysis Project, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
3. O'Reilly S and Rowinsky EK, The clinical status of irinotecan (CPT11), a novel water-soluble camptothecin analogue. Critic Rev Oncol Hematol 24: 47-70, 1996.
4. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P and Kelsen DP, Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J Clin Oncol 14: 2959-2967, 1996.
5. Yamao T, Shimada Y, Shirao K, Kondo H, Matsumura Y, Sugano K, Saito D, Ohtu A, Boku N, Yoshida S, Sasaki Y and Ono K, Phase I study of CPT11 combined with sequential 5FU in metastatic colorectal cancer. Proc of ASCO 15: 481, 1996.
6. Harstrick A, Vanhoefer U, Müller C, Achterrah W, Köhne H, Seeber S and Wilke H, Combination of CPT11 and 5FU in colorectal cancer: preclinical rationale and initial phase I results. Proc Am Assoc Cancer Res 38: 318, 1997.
7. Fonseca R, Goldberg RM, Erlichman C, Kaufman SH, Sloan JA and Miller LL, Phase I study of CPT11/5FU/leucovorin, Proc Am Assoc Cancer Res 38: 76, 1997.
8. Mans DRA, Brondani da Rocha, Vargas Schwartzbold C and Schwartsmann G, Assessments of the efficacy of the irinotecan (CPT11)-5fluorouracil (5FU) combination in a panel of human colon carcinoma cell lines. Proc Am Assoc Cancer Res 37: 29, 1996.
9. Grivicich I, Mans DRA, Da Rocha AB, Dalla Costa HS and Schwartsmann G, The cytotoxicity of the irinotecan (CPT11)-5fluorouracil (5FU) combination in human colon carcinoma cell lines is related to the sequence-dependent introduction of DNA lesions. Proc Am Assoc Cancer Res 38: 318, 1997.
10. Guichard S, Caliaro MJ, Houin G, Bugat R and Canal P, Sequential exposure to CPT11 and 5FU is synergistic in human colon carcinoma HT-29 cell line. Proc Am Assoc Cancer Res 37: 292, 1996.
11. Peters GJ, Van der Wilt CL, Van Triest B, Codacci-Pisanelli G, Johnston PG, Van Groeningen CJ and Pindeo HM, Thymidylate synthase and drug resistance. Eur J Cancer 31A: 1299-1305, 1995.
12. Chazal M, Cheradame S, Formento JL, Francoual M, Formento P, Etienne MC, François E, Richelme M, Mousseau M, Letoublon C, Pezet D, Cuve H, Seitz JF and Milano G, Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: Clinical data. Clin Cancer Res 3: 553-557, 1997.
13. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renée N and Milano G, A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30: 1517-1522, 1994.
14. Goldwasser F, Bae I, Valenti M, Torres K and Pommier Y, Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55: 2116-2121, 1995.
15. Carmichael J, De Graff WG, Gazdar AF, Minna JD and Mitchell JB, Evaluation of a tetrazolium-based semi-automated colorimetric assay in assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
16. Montero C and Llorente P, Single step LC method for determination of folylpolyglutamate synthetase activity and separation of folylpolyglutamates. Chromatographia 37: 73-78, 1993.
17. 4 Pteglu assays. In: The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy (Eds. Rustum Y and McGuire JJ), pp. 97-104. Plenum Press, New York, 1988.
18. Harris BE, Song R, Soong S and Diasio RB, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
19. Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP and Goldman ID, Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high-performance liquid chromatography. J Biol Chem 257: 8171-8176, 1982.
20. Vindelov LL, Christensen ID and Nissen NI, A detergent-trypsin method for the preparation of nuclei for flow cytometry DNA analysis. Cytometry 3: 323-327, 1983.
21. Baisch H, Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Rad Environ Biophys 12: 31-39, 1975.
22. Chou TC and Talalay P, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
23. Pinedo H and Peters GJ, Fluorouracil, biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
24. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW and Pommier Y, Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56: 4430-4437, 1996.
25. Kaakaji R, Morimura T, Kikuchi H, Takeuchi J and Barnett GH, Induction of apoptosis in multidrug-resistant human glioblastoma cells by SN38, a metabolite of the camptothecin derivative CPT11. Cancer Chemother Pharmacol 39: 417-426, 1997.
26. Zeghari-Squalli N, Misset JL and Goldwasser F, Mechanism of the in vitro interaction between SN38 and 5FU. Proc Am Assoc Cancer Res 38: 3, 1997.
27. Guichard S, Hennebelle F, Bugat R and Canal P, Cellular interactions of 5-fluorouracil and CPT11 in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676, 1998.
28. Pourquier P, Ueng LM, Kohlhagen G, Mazumber A, Gupta M, Kohn KW and Pommier Y, Effects of uracil incorporation, DNA mismatches and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 272: 7792-7796, 1997.
29. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L, Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
30. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Buranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV, Quantification of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.